{"id":36756,"date":"2025-07-04T18:21:16","date_gmt":"2025-07-04T10:21:16","guid":{"rendered":"https:\/\/flcube.com\/?p=36756"},"modified":"2025-07-04T18:21:17","modified_gmt":"2025-07-04T10:21:17","slug":"jiangsu-vcare-pharmatechs-vc004-nda-accepted-for-review-by-chinas-nmpa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36756","title":{"rendered":"Jiangsu Vcare PharmaTech&#8217;s VC004 NDA Accepted for Review by China&#8217;s NMPA"},"content":{"rendered":"\n<p>China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004 has been accepted for review by the National Medical Products Administration (NMPA). Previously granted priority review status, this next-generation anti-drug resistance TRK inhibitor is anticipated to offer a novel therapeutic option for patients suffering from advanced solid tumors.<\/p>\n\n\n\n<p><strong>Indication and Usage<\/strong><br>VC004, a Category 1 small molecule targeted anti-tumor drug, is indicated for the treatment of adult and adolescent patients aged 12 and above with solid tumors harbouring the neurotrophin tyrosine receptor kinase (NTRK) fusion gene. This includes patients with locally advanced, metastatic disease, or scenarios where surgical resection may lead to severe complications. It also targets those with no satisfactory alternative treatments or prior treatment failures.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36757,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,38,68,573],"class_list":["post-36756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-market-approval-filings","tag-pediatric-drugs","tag-vcare-pharmatech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Vcare PharmaTech&#039;s VC004 NDA Accepted for Review by China&#039;s NMPA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004 has been accepted for review by the National Medical Products Administration (NMPA). Previously granted priority review status, this next-generation anti-drug resistance TRK inhibitor is anticipated to offer a novel therapeutic option for patients suffering from advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36756\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Vcare PharmaTech&#039;s VC004 NDA Accepted for Review by China&#039;s NMPA\" \/>\n<meta property=\"og:description\" content=\"China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004 has been accepted for review by the National Medical Products Administration (NMPA). Previously granted priority review status, this next-generation anti-drug resistance TRK inhibitor is anticipated to offer a novel therapeutic option for patients suffering from advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36756\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-04T10:21:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-04T10:21:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0421.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Vcare PharmaTech&#8217;s VC004 NDA Accepted for Review by China&#8217;s NMPA\",\"datePublished\":\"2025-07-04T10:21:16+00:00\",\"dateModified\":\"2025-07-04T10:21:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756\"},\"wordCount\":137,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0421.webp\",\"keywords\":[\"Cancer\",\"Market approval filings\",\"Pediatric drugs\",\"Vcare PharmaTech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36756#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36756\",\"name\":\"Jiangsu Vcare PharmaTech's VC004 NDA Accepted for Review by China's NMPA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0421.webp\",\"datePublished\":\"2025-07-04T10:21:16+00:00\",\"dateModified\":\"2025-07-04T10:21:17+00:00\",\"description\":\"China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004 has been accepted for review by the National Medical Products Administration (NMPA). Previously granted priority review status, this next-generation anti-drug resistance TRK inhibitor is anticipated to offer a novel therapeutic option for patients suffering from advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36756\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0421.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0421.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Vcare PharmaTech's VC004 NDA Accepted for Review by China's NMPA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36756#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Vcare PharmaTech&#8217;s VC004 NDA Accepted for Review by China&#8217;s NMPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Vcare PharmaTech's VC004 NDA Accepted for Review by China's NMPA - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004 has been accepted for review by the National Medical Products Administration (NMPA). Previously granted priority review status, this next-generation anti-drug resistance TRK inhibitor is anticipated to offer a novel therapeutic option for patients suffering from advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36756","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Vcare PharmaTech's VC004 NDA Accepted for Review by China's NMPA","og_description":"China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004 has been accepted for review by the National Medical Products Administration (NMPA). Previously granted priority review status, this next-generation anti-drug resistance TRK inhibitor is anticipated to offer a novel therapeutic option for patients suffering from advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=36756","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-04T10:21:16+00:00","article_modified_time":"2025-07-04T10:21:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0421.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36756#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36756"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Vcare PharmaTech&#8217;s VC004 NDA Accepted for Review by China&#8217;s NMPA","datePublished":"2025-07-04T10:21:16+00:00","dateModified":"2025-07-04T10:21:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36756"},"wordCount":137,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36756#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0421.webp","keywords":["Cancer","Market approval filings","Pediatric drugs","Vcare PharmaTech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36756#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36756","url":"https:\/\/flcube.com\/?p=36756","name":"Jiangsu Vcare PharmaTech's VC004 NDA Accepted for Review by China's NMPA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36756#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36756#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0421.webp","datePublished":"2025-07-04T10:21:16+00:00","dateModified":"2025-07-04T10:21:17+00:00","description":"China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004 has been accepted for review by the National Medical Products Administration (NMPA). Previously granted priority review status, this next-generation anti-drug resistance TRK inhibitor is anticipated to offer a novel therapeutic option for patients suffering from advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36756#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36756"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36756#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0421.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0421.webp","width":1080,"height":608,"caption":"Jiangsu Vcare PharmaTech's VC004 NDA Accepted for Review by China's NMPA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36756#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Vcare PharmaTech&#8217;s VC004 NDA Accepted for Review by China&#8217;s NMPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0421.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36756"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36756\/revisions"}],"predecessor-version":[{"id":36758,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36756\/revisions\/36758"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36757"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}